The highlighter squeaks-a dry, rhythmic scratching against 48-pound bond paper-as Dr. Arispe circles a typo on page 118 of the informed consent form. The air in the conference room is stale, filtered through a ventilation system that hasn’t been cleaned since the Reagan administration, and I am watching João E., our ergonomics consultant, adjust the height of his ergonomic stool with a series of precise, hydraulic clicks. He isn’t looking at the protocol. He’s looking at the way Arispe’s neck crumbles under the weight of 28 consecutive pages of adverse event procedures. We are here to decide if a phase II study is ‘ethical,’ but the ethics we are discussing are entirely procedural, a theater of checkboxes and font-size requirements that somehow completely ignores the white powder at the center of the storm.

I’m thinking about my phone, or rather, the void inside it. Last night, I accidentally deleted three years and eight months of photos. Thousands of moments-the lighting in a Copenhagen hotel, my niece’s graduation, the specific way the sun hit my desk in 2018-gone because I clicked ‘confirm’ on a storage management prompt I didn’t fully read. It was a procedural error with a permanent material consequence. This IRB meeting feels the same. We are clicking ‘confirm’ on protocols while the material provenance of the investigational compounds remains a digital ghost. We spend 58 minutes debating the linguistic nuance of ‘minimal risk’ for a blood draw, yet not a single person in this room has asked for a Certificate of Analysis (COA) or a mass spectrometry report for the peptides being injected into the 118 participants.

João E. catches my eye and whispers that the table height is at least 8 centimeters too low for a woman of Arispe’s stature. He’s obsessed with the physical interaction between the human body and the tools of labor. I wish the IRB shared that obsession regarding the chemicals we put into those bodies. The disconnect is staggering. An IRB will demand a 48-page dossier on how we plan to store patient records in a double-locked cabinet with 128-bit encryption, but they will accept ‘reagent grade compound’ as a sufficient description for the actual substance being studied. It’s as if we’ve decided that if the paperwork is sufficiently heavy, the chemistry must be sufficiently pure.

We are operating in a landscape where the supply chain has been outsourced to the lowest bidder on a global marketplace, and yet the ethical framework remains tethered to a 1970s model where everything came from a trusted domestic pharmacy. When we submit these protocols, we are essentially saying, ‘Trust us, the stuff in the vial is what the label says.’ And the IRB, exhausted by the sheer volume of 18-point font disclaimers, simply nods. They have been trained to look for procedural protection, not material truth. They worry about the ergonomics of the consent process-can the patient read it? Is the room quiet?-while the molecular structure of the peptide remains an unverified promise.

I’ve seen labs where the synthesis records are as fragmented as my deleted photo library. You ask for a batch record and you get a shrug or a PDF from a factory in a province you can’t pronounce. This isn’t just a technical oversight; it’s an ethical chasm. If the reagent is 98% pure, what is the other 2%? Is it TFA? Is it a truncated sequence? Is it a residual solvent that will cause a localized inflammatory response that we will then misinterpret as a drug effect? The IRB doesn’t ask because the IRB assumes that ‘sourcing’ is a logistical problem, not a moral one. But ethics without provenance is just paperwork.

João E. stands up to demonstrate the correct lumbar support for the board members, his movements fluid and practiced. He’s trying to save their spines, but who is saving the integrity of the data? There’s a certain irony in the fact that we are so meticulous about the ergonomics of the review process-the 8-minute breaks, the adjustable chairs, the water carafes-while being so reckless about the physical reality of the investigational product. We’ve built a fortress of bureaucracy around a foundation of sand. We believe that if we follow the rules of the Belmont Report, we are protected. But the Belmont Report didn’t anticipate a world where you can buy a complex peptide from a website with no physical address and inject it into a human being under the banner of ‘research.’

This is where companies like

ProFound Peptides

become more than just vendors; they become the silent partners in a material ethics that the IRB has forgotten. They provide the documentation that proves the molecule is what we say it is. They close the gap between the procedural ‘yes’ and the chemical ‘truth.’ In a world where I can lose 3,218 photos with a thumb-slip, I find a strange, grounding comfort in a rigorous COA. It is a record. It is a witness. It is the material history that prevents a study from becoming a fiction.

Arispe finally stops highlighting. She looks up, her neck visibly strained from the 58 minutes of poor posture João E. warned us about. ‘The informed consent looks good,’ she says. ‘The risk-benefit ratio for the lumbar puncture is acceptable.’ I want to ask her if she knows where the peptide came from. I want to ask if she knows the difference between a research-grade compound and a clinical-grade one. But the protocol doesn’t require it. The regulations don’t mandate it. We are all complicit in this administrative theater. We have decided that the ‘subject’ is a collection of rights and signatures, rather than a biological entity interacting with a specific, physical substance.

I remember one particular photo I lost-a shot of a lab bench in 2018, messy with pipettes and a single, unlabelled amber vial. It was a reminder of how easily things become anonymous. Without the metadata, that vial could be anything. Without the supply chain documentation, our research compounds are just anonymous vials. We are gambling with the safety of 48 people based on the assumption that the market is inherently honest. It’s a dangerous bet. The IRB’s silence on sourcing is a symptom of a deeper malaise: the belief that the map (the protocol) is the territory (the actual biological experiment).

João E. is now lecturing on the importance of wrist angles when typing up meeting minutes. He’s right, of course. Small misalignments over long periods cause structural failure. The same is true for our ethics. The small misalignment of ignoring reagent provenance for 28 years has led to a structural failure in the integrity of our clinical trials. We have protocols that are ergonomically perfect for the bureaucracy but physically dangerous for the participants. We’ve optimized for the process and ignored the product.

I think back to the 188-page manual on laboratory safety that sits on my shelf. It’s filled with rules about eye washes and lab coats, yet it says almost nothing about the verification of the chemicals themselves. It’s as if we believe that if we wear the right gear and fill out the right forms, the molecules will behave. But the molecules don’t care about our forms. They only care about their own structure, their own purity, their own presence. If we don’t verify that presence, we are just performing a ritual.

The board moves to a vote. Eight hands go up. The protocol is approved. Dr. Arispe sighs, a sound of profound fatigue, and begins to pack her 48-page document into a leather briefcase. João E. gives me a thumbs-up; he’s satisfied with the chair adjustments he made during the recess. He saved a few lower backs today. But as I walk out of the room, thinking about those 3,800 lost photos and the unasked questions about the peptide synthesis, I realize that we are all just squinting at a screen, hoping the image we’re looking at is real, while having no way to prove where it came from. We’ve managed to create a system that is perfectly ergonomic for the reviewers, but fundamentally unstable for the science. We are protecting the process, but we’ve forgotten to protect the truth.